Mallinckrodt PLC | Ownership
Companies that own Mallinckrodt PLC
BlackRock Fund Advisors
8,840,407
10.62%
1,252,027
0.02%
06/30/2018
Scopia Capital Management LP
7,672,212
9.22%
-954,153
4.54%
06/30/2018
The Vanguard Group, Inc.
7,328,128
8.81%
-719,315
0.01%
06/30/2018
Deerfield Management Company LP
6,988,248
8.4%
-1,633,135
6.88%
06/30/2018
Dimensional Fund Advisors LP
4,422,787
5.32%
345,385
0.04%
06/30/2018
SSgA Funds Management, Inc.
3,687,135
4.43%
43,457
0.01%
06/30/2018
Paulson & Co., Inc.
3,670,992
4.41%
0
2.38%
06/30/2018
Miller Value Partners LLC
3,338,025
4.01%
1,218,750
3.85%
06/30/2018
LSV Asset Management
2,675,154
3.22%
48,437
0.12%
06/30/2018
Hotchkis & Wiley Capital Management LLC
2,606,240
3.13%
-95,300
0.32%
06/30/2018
| Address |
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
United Kingdom
|
|
Employees
|
- |
| Website |
http://mallinckrodt.com |
| Updated |
07/08/2019 |
| Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. |
